Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
110
archived clinical trials in
Genital Herpes

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
226
mi
from 98109
Spokane, WA
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
226
mi
from 98109
Spokane, WA
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1514
mi
from 98109
La Crosse, WI
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1514
mi
from 98109
La Crosse, WI
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1687
mi
from 98109
Milwaukee, WI
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1673
mi
from 98109
Waukesha, WI
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1673
mi
from 98109
Waukesha, WI
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
6918
mi
from 98109
Buenos Aires,
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
6918
mi
from 98109
Buenos Aires,
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Alabama Vaccine Research Clinic; University of Alabama at Birmingham
2079
mi
from 98109
Birmingham, AL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Alabama Vaccine Research Clinic; University of Alabama at Birmingham
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
1062
mi
from 98109
San Diego, CA
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
1062
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
QPS Broward Research
mi
from 98109
Hollywood, FL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
QPS Broward Research
mi
from 98109
Hollywood, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
QPS Miami Research Associates
2730
mi
from 98109
South Miami, FL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
QPS Miami Research Associates
2730
mi
from 98109
South Miami, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Comprehensive Clinical Trials
2691
mi
from 98109
West Palm Beach, FL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Comprehensive Clinical Trials
2691
mi
from 98109
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Univ of Illinois
1730
mi
from 98109
Chicago, IL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Univ of Illinois
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Indiana University Infectious Disease Research
1868
mi
from 98109
Indianapolis, IN
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Indiana University Infectious Disease Research
1868
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
1440
mi
from 98109
Wichita, KA
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
1440
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Central Kentucky Research Associates, Inc.
2010
mi
from 98109
Lexington, KY
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Central Kentucky Research Associates, Inc.
2010
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
1507
mi
from 98109
Kansas City, MO
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
1507
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
2160
mi
from 98109
Rochester, NY
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
2160
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
University of North Carolina (UNC) Institute of Global Health and Infectious Diseases
mi
from 98109
Chapel Hill, NC
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
University of North Carolina (UNC) Institute of Global Health and Infectious Diseases
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates
1971
mi
from 98109
Nashville, TN
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
University of Utah School of Medicine - Division of Infectious Diseases
mi
from 98109
Salt Lake City, UT
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
University of Utah School of Medicine - Division of Infectious Diseases
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
1062
mi
from 98109
San Diego, CA
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
1062
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Optimus Medical Group
934
mi
from 98109
San Francisco, CA
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Optimus Medical Group
934
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
UNC Health
mi
from 98109
Chapel Hill, NC
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
UNC Health
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
NW Dermatology and Research Clinic
mi
from 98109
Portland, OR
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
NW Dermatology and Research Clinic
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Tekton Research
1770
mi
from 98109
Austin, TX
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Tekton Research
1770
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
Indiana University School of Medicine, IU Infectious Diseases Research
1868
mi
from 98109
Indianapolis, IN
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
Indiana University School of Medicine, IU Infectious Diseases Research
1868
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
Westover Heights Clinic
147
mi
from 98109
Portland, OR
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
Westover Heights Clinic
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
University of Texas Health Science Centre, Center for Clincial Studies
1890
mi
from 98109
Houston, TX
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
University of Texas Health Science Centre, Center for Clincial Studies
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
University of Washington, Virology Research Clinic
2
mi
from 98109
Seattle, WA
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
University of Washington, Virology Research Clinic
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
Status: Enrolling
Updated:  7/2/2015
University of Washington Virology Research Clinic
2
mi
from 98109
Seattle, WA
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
Status: Enrolling
Updated: 7/2/2015
University of Washington Virology Research Clinic
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status: Enrolling
Updated:  10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status: Enrolling
Updated: 10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
626
mi
from 98109
Sacramento, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
626
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
949
mi
from 98109
Westlake Village, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
949
mi
from 98109
Westlake Village, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1020
mi
from 98109
Denver, CO
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
2701
mi
from 98109
Boynton Beach, FL
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
2701
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
2730
mi
from 98109
Miami, FL
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1892
mi
from 98109
Madisonville, KY
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1892
mi
from 98109
Madisonville, KY
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
666
mi
from 98109
Billings, MT
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
666
mi
from 98109
Billings, MT
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
1366
mi
from 98109
Omaha, NE
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials